SCHEMBL217973

SCHEMBL217973

c1ccc2c(c1)CSO2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1724509 1.00 MAOA (0.42)
Pyrrolidine SCHEMBL10964545 0.86 OXTR (0.40)
SCHEMBL10504181 0.82 ACHE (0.41)
SCHEMBL731982 0.76 MAOA (0.39)
SCHEMBL29655819 0.76 MAOA (0.39)
SCHEMBL1724300 0.76 MAOA (0.39)
SCHEMBL375376 0.76 MAOA (0.39)
SCHEMBL9119817 0.73 TSHR (0.42)
SCHEMBL4502914 0.73 TSHR (0.42)
SCHEMBL15789324 0.70 MAOA (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3658141-B1 TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTION STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) 2022-11-16 EP claimed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US claimed
EP-1713780-B1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2012-01-18 EP claimed
JP-4806628-B2 2011-11-02 JP claimed
US-20100159032-A1 COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS PROBIODRUG AG (DE) 2010-06-24 US claimed
EP-1620091-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2010-03-31 EP claimed
US-7655684-B2 1-(Urea-, thiourea- and cyanoguanidine-methylene)benzyl)imidaoles, treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson's disease and Huntington's disease PROBIODRUG AG (DE) 2010-02-02 US claimed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP claimed
US-20080153892-A1 Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-06-26 US claimed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US claimed
US-7371871-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2008-05-13 US claimed
US-20060235222-A1 Indole-derivative modulators of steroid hormone nuclear receptors ELI LILLY AND COMPANY (US) 2006-10-19 US claimed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP claimed
EP-1620091-A2 INHIBITORS OF GLUTAMINYL CYCLASE Probiodrug AG (DE) 2006-02-01 EP claimed
EP-1597254-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS Eli Lilly and Company (US) 2005-11-23 EP claimed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO claimed
WO-2004098591-A2 INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES PROBIODRUG AG (DE) 2004-11-18 WO claimed
US-20040224875-A1 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2004-11-11 US claimed
WO-2004067529-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS ELI LILLY AND COMPANY (US) 2004-08-12 WO claimed
US-5098806-A Photochromic film filter turning opaque prior to copier's light; reverts to transparent BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1992-03-24 US claimed